Complete Case or Full Dataset? Choosing the Right Analysis Approach for Missing Data

Handling missing data is a critical decision in clinical trial analysis. Two commonly considered approaches are Complete Case Analysis (CCA) and Full Dataset Modeling (e.g., MMRM or Multiple Imputation). Choosing between them requires understanding the underlying assumptions, data structure, regulatory expectations, and impact on validity.

This guide explores when it is appropriate to use complete case analysis versus full dataset methods in biostatistical evaluations. We’ll also discuss the regulatory context from agencies like the USFDA and EMA, and offer practical recommendations to guide your decision-making process.

Understanding Complete Case Analysis (CCA)

Complete Case Analysis involves analyzing only those subjects for whom all relevant data are available. Any patient with missing data on the outcome or a key covariate is excluded from the analysis.

Advantages of CCA:

• Simple to implement and interpret
• Works with standard statistical tools
• No modeling assumptions about the missing data

Limitations of CCA:

• Leads to loss of sample size and statistical power
• Results may be biased if data are not Missing Completely at Random (MCAR)
• Cannot be used when missingness is high or systematic

When to Use CCA:

• When the proportion of missing data is low (<5%)
• When data are MCAR (i.e., probability of missingness is unrelated to both observed and unobserved data)
• When conducting exploratory or supportive analyses

CCA may be acceptable under specific circumstances, but its limitations must be clearly stated in the trial documentation.

Understanding Full Dataset Analysis

Full Dataset Analysis refers to techniques that incorporate all available data, including cases with partial information. Examples include:

• MMRM (Mixed Models for Repeated Measures): Accommodates MAR (Missing at Random) data
• Multiple Imputation: Uses observed data to predict and fill in missing values
• Maximum Likelihood Estimation: Accounts for partial data without explicit imputation

Advantages of Full Dataset Methods:

• Preserves statistical power by using all available information
• Yields unbiased estimates under MAR assumptions
• Widely accepted by regulatory agencies

Limitations:

• Requires correct specification of the model
• May be computationally intensive
• Assumptions (like MAR) must be justified

These methods are favored in regulatory reviews, especially for primary endpoints. Their inclusion in the Statistical Analysis Plan reflects best practice in handling missing data.

Regulatory Guidance: CCA vs Full Dataset

Regulators discourage CCA as a primary analysis method unless MCAR can be assumed and justified. For pivotal trials, agencies like the FDA and EMA recommend full dataset approaches with appropriate sensitivity analyses.

Key Guidelines:

• FDA Guidance on Missing Data (2010): Emphasizes pre-specification and avoidance of CCA
• ICH E9(R1): Introduces estimands that define the role of intercurrent events like dropout
• EMA Guideline on Missing Data: Encourages model-based analyses with sensitivity checks

Documentation of methods and justification of assumptions is critical for regulatory compliance.

Practical Comparison: When to Choose What

Best Practices for Implementation

• Include both CCA and full dataset methods in SAP as primary and supportive analyses
• Clearly define assumptions about missing data mechanisms
• Perform and report sensitivity analyses (e.g., tipping point, delta adjustment)
• Use statistical software with validated imputation modules
• Document rationale and results per SOPs and in the CSR

Conclusion

The decision to use complete case analysis or full dataset modeling should be driven by data characteristics, missingness mechanisms, and regulatory requirements. While CCA is easy to apply, it is limited to rare MCAR situations and should only be used as supportive analysis. Full dataset approaches like MMRM and multiple imputation offer robust solutions under MAR and are preferred in regulatory submissions. Incorporating both strategies—alongside transparent assumptions and sensitivity analyses—ensures your trial results remain valid and defensible.

How to Use LOCF, MMRM, and Multiple Imputation in Clinical Trials

Handling missing data in clinical trials is a critical challenge that can significantly affect the integrity and reliability of study results. Patient dropouts, missed visits, and unrecorded outcomes are common, and how we address these gaps can influence regulatory decisions. To ensure robustness and minimize bias, biostatisticians use various imputation methods to estimate missing values based on observed data patterns.

Among the most widely used methods are Last Observation Carried Forward (LOCF), Mixed Models for Repeated Measures (MMRM), and Multiple Imputation (MI). Each technique has strengths and limitations, and their selection must align with the type of missing data—whether it’s Missing Completely at Random (MCAR), Missing at Random (MAR), or Missing Not at Random (MNAR).

This article offers a practical guide for selecting and applying imputation strategies in clinical trial analysis. It also reflects regulatory expectations from the USFDA and EMA, ensuring compliance with ICH guidelines and audit-readiness of your results.

1. Last Observation Carried Forward (LOCF)

What It Is:

LOCF replaces missing values with the last available observed value for that subject. It is simple and has historically been popular, especially in longitudinal studies measuring repeated outcomes such as symptom scores.

How It Works:

Suppose a subject completed Week 4 but missed Week 6 and 8 visits. LOCF will use their Week 4 value to fill in the missing timepoints.

Advantages:

• Simple to implement in most software (R, SAS, SPSS)
• Maintains the original sample size
• Helpful in sensitivity analyses

Limitations:

• Assumes no change after last observation (often unrealistic)
• Can underestimate variability and bias treatment effects
• Discouraged by regulators as a primary analysis method

Despite limitations, LOCF can still be included in pharma SOPs as a supplementary method during sensitivity analysis.

2. Mixed Models for Repeated Measures (MMRM)

What It Is:

MMRM uses all available observed data points and models the outcome over time. It assumes missing data are MAR and incorporates time as a fixed effect and subjects as random effects. Unlike LOCF, it doesn’t impute values explicitly but estimates them via maximum likelihood.

How It Works:

Each subject’s data trajectory contributes to the overall likelihood function. MMRM adjusts for baseline covariates and can accommodate unequally spaced visits and dropout patterns.

Advantages:

• Preferred by regulators when MAR assumption holds
• Statistically efficient and unbiased under MAR
• Handles unbalanced data without needing imputation

Limitations:

• Complex to implement and interpret
• Assumes missingness depends only on observed data
• Inappropriate for MNAR data

MMRM is frequently used in pivotal trials involving longitudinal measurements, such as HbA1c in diabetes or depression scores in CNS studies. It is a key strategy outlined in GMP documentation and SAPs for confirmatory trials.

3. Multiple Imputation (MI)

What It Is:

MI fills in missing data by creating several plausible values based on observed data patterns. These multiple datasets are analyzed separately, and results are pooled using Rubin’s rules to account for imputation uncertainty.

How It Works:

1. Create multiple complete datasets using random draws from a predictive distribution
2. Analyze each dataset using the same statistical model
3. Combine estimates and standard errors across datasets

Advantages:

• Accounts for uncertainty and variability in imputed values
• Applicable under MAR, flexible with data types
• Recommended by EMA and FDA when LOCF or complete-case analysis is inappropriate

Limitations:

• Requires expert statistical knowledge to implement correctly
• Subject to model misspecification risks
• Computationally intensive for large datasets

MI is a robust method often included in primary or secondary analyses of stability studies and efficacy endpoints, especially when data collection spans long periods.

Comparison of Imputation Methods

Regulatory Perspective

Regulators like EMA and CDSCO expect sponsors to:

• Specify primary and sensitivity imputation methods in the Statistical Analysis Plan
• Justify the choice of method based on the assumed missing data mechanism
• Conduct multiple imputation when data is MAR and analyze different patterns
• Perform sensitivity analyses to assess robustness of results

Inadequate handling of missing data can jeopardize trial approval, particularly when survival or patient-reported outcomes are endpoints.

Best Practices for Implementing Imputation

1. Define your imputation strategy in the trial protocol and SAP
2. Use validated software (e.g., SAS PROC MI, R mice package, SPSS missing values module)
3. Avoid relying solely on LOCF for primary analyses
4. Run multiple imputation diagnostics (convergence, plausibility)
5. Include assumptions and imputation details in Clinical Study Reports

Conclusion

Effective handling of missing data through LOCF, MMRM, or Multiple Imputation is essential for unbiased, credible, and regulatory-compliant clinical trial results. While LOCF is simple, it carries assumptions that may not reflect real-world progression. MMRM offers model-based strength for longitudinal designs, and Multiple Imputation provides a statistically sound approach under MAR assumptions. Selection of the right method should be data-driven, pre-specified, and backed by best practices from the fields of pharma validation and biostatistics. In the ever-evolving landscape of drug development, a thoughtful imputation strategy can mean the difference between success and setback.